Cendifensine

Cendifensine
Clinical data
Other namesNOE-115
Drug classMonoamine reuptake inhibitor
Identifiers
  • (3,4-dichlorophenyl)-[(3S)-3-propylpyrrolidin-3-yl]methanone
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC14H17Cl2NO
Molar mass286.20 g·mol−1
3D model (JSmol)
  • CCC[C@@]1(CCNC1)C(=O)C2=CC(=C(C=C2)Cl)Cl
  • InChI=1S/C14H17Cl2NO/c1-2-5-14(6-7-17-9-14)13(18)10-3-4-11(15)12(16)8-10/h3-4,8,17H,2,5-7,9H2,1H3/t14-/m0/s1
  • Key:HVLPRTLORBIKNG-AWEZNQCLSA-N

Cendifensine (INNTooltip International Nonproprietary Name) is a monoamine reuptake inhibitor (MRI) related to the amphetamines and cathinones which has not been marketed at this time. It was first described by 2013 and its INNTooltip International Nonproprietary Name was proposed in 2024. The drug has been patented by Noema Pharma, which is developing a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) known as NOE-115 for the treatment of vasomotor symptoms associated with menopause as well as for binge-eating disorder and depressive disorders.

See also

References

  1. ↑ WO 2023/161533A1, Garibaldi G, "Triple uptake inhibitor for the treatment of atypical depression", published 31 August 2023, assigned to Noema Pharma AG
  2. 1 2 "Proposed INN: List 132 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 38 (4). 2024. cendifensinum cendifensine (3,4-dichlorophenyl)[(3S)-3-propylpyrrolidin-3-yl]methanone monoamine reuptake inhibitor [...] C14H17Cl2NO 1034048-49-1
  3. ↑ "(3,4-Dichlorophenyl)[(3S)-3-propyl-3-pyrrolidinyl]methanone". Global Substance Registration System (GSRS). National Center for Advancing Translational Sciences (NCATS), U.S. National Institutes of Health. Retrieved 24 February 2025.
  4. 1 2 CA 2860810A1, Adam JM, Dvorak CA, Fishlock D, Humphreys ER, Iding H, Pfleger C, Rege PD, Shi X, Vitale J, Wang S, Zajac M, "(3,4-dichloro-phenyl)-((s)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride and manufacturing processes", published 23 April 2013, assigned to F Hoffmann La Roche AG
  5. ↑ Young Moss S, Lee A, Simon JA (November 2025). "Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms". Drugs. 85 (11): 1363–1379. doi:10.1007/s40265-025-02231-8. PMC 12572072. PMID 41028653.
  6. ↑ "NOE 115". AdisInsight. 21 May 2024. Retrieved 24 February 2025.
  7. ↑ "Delving into the Latest Updates on Noema Pharma AG with Synapse". Synapse. 23 January 2025. Retrieved 24 February 2025.
  8. ↑ "Noema Pharma". Noema Pharma. 18 June 2021. Retrieved 24 February 2025.